Castle Biosciences Inc CSTL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
New Data at AFS 2024 Demonstrates the Strength of Castle Biosciences’ TissueCypher® Test in Independently Predicting Risk of Developing Esophageal Cancer, Guiding Risk-Aligned Management Decisions for Patients with Barrett’s Esophagus
-
Castle Biosciences’ Chief Operating Officer Kristen Oelschlager Named Arizona Bioscience Leader of the Year
-
DecisionDx®-Melanoma Can Identify Melanoma Patients with Low Risk of Sentinel Lymph Node Positivity Who May Safely Forego Biopsy Surgery, New Independent Study Affirms
-
Study Confirms the Ability of Castle Biosciences' DecisionDx®-SCC Test to Predict Likelihood of Benefit from Adjuvant Radiation Therapy in Patients with High-Risk Cutaneous Squamous Cell Carcinoma
-
Castle Biosciences to Participate in Upcoming Investor Conferences
-
Castle Biosciences Reports Second Quarter 2024 Results
-
Castle Biosciences to Present at the Canaccord Genuity 44th Annual Growth Conference
-
Castle Biosciences and Skin Cancer Survivor Teddi Mellencamp Arroyave Launch Campaign to Increase Awareness of Melanoma
Trading Information
- Previous Close Price
- $28.60
- Day Range
- $27.96–29.14
- 52-Week Range
- $12.07–32.53
- Bid/Ask
- $24.03 / $31.00
- Market Cap
- $776.63 Mil
- Volume/Avg
- 310,172 / 419,373
Key Statistics
- Price/Earnings (Normalized)
- 234.08
- Price/Sales
- 2.70
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Small Growth
- Total Number of Employees
- 703
Comparables
Valuation
|
Metric
|
CSTL
|
VCYT
|
PSNL
|
|---|---|---|---|
Price/Earnings (Normalized) | 234.08 | 75.24 | — |
Price/Book Value | 1.83 | 2.27 | 2.44 |
Price/Sales | 2.70 | 6.27 | 3.25 |
Price/Cash Flow | 14.71 | 37.13 | — |
Price/Earnings
CSTL
VCYT
PSNL
Financial Strength
|
Metric
|
CSTL
|
VCYT
|
PSNL
|
|---|---|---|---|
Quick Ratio | 7.75 | 3.96 | 2.93 |
Current Ratio | 8.12 | 4.44 | 3.31 |
Interest Coverage | −54.71 | −13,015.40 | −2,072.48 |
Quick Ratio
CSTL
VCYT
PSNL
Profitability
|
Metric
|
CSTL
|
VCYT
|
PSNL
|
|---|---|---|---|
Return on Assets (Normalized) | 7.97% | 9.55% | −29.69% |
Return on Equity (Normalized) | 9.08% | 10.25% | −46.55% |
Return on Invested Capital (Normalized) | 6.49% | 9.19% | −37.04% |
Return on Assets
CSTL
VCYT
PSNL
Diagnostics & Research Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc
TMO
| Lszvtlwmg | Drhsh | $236.6 Bil | |||
| Danaher Corp
DHR
| Zfctwmlrq | Dxpbx | $200.0 Bil | |||
| IQVIA Holdings Inc
IQV
| Skpydsmkb | Xsbqd | $43.1 Bil | |||
| Agilent Technologies Inc
A
| Trnjjnhkld | Rjckj | $42.2 Bil | |||
| IDEXX Laboratories Inc
IDXX
| Xytpycpyf | Vvzb | $41.9 Bil | |||
| Mettler-Toledo International Inc
MTD
| Sdvhdtlv | Yqbfnb | $31.6 Bil | |||
| Icon PLC
ICLR
| Ytqnjgcj | Dklks | $23.7 Bil | |||
| Waters Corp
WAT
| Znpkpswmkm | Rvwg | $21.1 Bil | |||
| Illumina Inc
ILMN
| Pvhpxtfqr | Nzhjlxg | $21.1 Bil | |||
| Labcorp Holdings Inc
LH
| Zpqkrzbgy | Xtsxyz | $18.5 Bil |
United States